Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Changchun Bao Oral Liquid (长春宝口服液) is a traditional Chinese medicine (TCM) oral solution developed and manufactured by Wuhan Juneng Golden Key Pharmaceutical Co., Ltd. The formulation is composed of 24 herbal ingredients, including Ginseng, Astragalus, and Rehmannia glutinosa, which work synergistically to tonify Qi and Blood, harmonize Yin and Yang, and nourish the liver, kidney, spleen, and stomach. It is specifically indicated for middle-aged and elderly individuals suffering from symptoms of physical decline and deficiency, such as fatigue, dizziness, tinnitus, insomnia, and palpitations. As a complex herbal mixture, its therapeutic effects are attributed to the holistic principles of TCM rather than a single pharmacological target. The product is approved in China under the National Medicine Standard.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Changchun Bao Oral Liquid.